Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

How to "Choosebetweenamab" for Severe Asthma, Comparing Treatment With Mepolizumab and Omalizumab for Patients With Severe Allergic and Eosinophilic Asthma.

NCT04585997 is registered in ClinicalTrials.gov with University of Newcastle, Australia as lead sponsor.

NCT NCT04585997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04585997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
How to "Choosebetweenamab" for Severe Asthma, Comparing Treatment With Mepolizumab and Omalizumab for Patients With Severe Allergic and Eosinophilic Asthma.
Lead sponsor
University of Newcastle, Australia
Phase
Phase 4
Overall status
Unknown status
Start date
November 3, 2018
Completion date
December 31, 2022
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, eosinophilic asthma